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Background: Poor response to aspirin (ASA) in patients with peripheral arterial disease (PAD) can be a major problem. Based on 1 measurement 
of arachidonic acid (AA) induced platelet aggregation, we previously reported that poor response to ASA (PNR) in PAD patients may be as high as 
24%. Given possible non-compliance we tested the rate of persistent PNR. Additionally we evaluated the other clinically used measures to test 
aspirin response including the Platelet Function Analyzer (PFA)-100 epinephrine closure time and optical aggregometry with adenosine diphosphate 
(ADP).
Methods: PAD patients (n=74), on ASA who had platelet function testing (optical aggregometry with arachidonic acid (AA) and adenosine 
diphosphate (ADP), PFA-100 with collagen/ADP (cADP) and collagen/epinephrine (cEPI) cartridges) at baseline and follow up [6 months (n=70), 
12 months (n=56), or both (n=54)] were included. PNR was defined as AA induced platelet aggregation >30%. Continuous variables are reported as 
mean ± SD.
Results: At baseline, 16.2% (n=12) had AA aggregation >30%. All 12 individuals were tested at 6 month and 8 of them at 12 month follow up. 
At 6 months, 7.1% (n=5) and at 12 months 5.3% (n=3) remained PNR. There were no differences in the PFA closure time between PNR and ASA 
responders at baseline (cADP 124±38 p=0.52, and cEPI 183.8±73 p=0.17), at 6 month (173±116.3 p=0.33, and 179.4±110.5 p=0.29), and 
at 12 month (168±114.4 p=0.56, and 165.7±116.6 p=0.5) respectively. No difference was found in ADP aggregometry between PNR and ASA 
responders (58.2±37.8 vs. 65.7±29.6, p=0.69) at baseline, 6 month (p=0.92), or 12 month (p=0.96). However, patients who were initially PNR 
and subsequently ASA responsive had significantly shorter cEPI times than patients who remained ASA responsive (125.5 ± 31.8 vs. 238.6 ± 81, 
p<0.001).
Conclusion: These data suggest that 1) 5.3-7.1% of PAD patients respond poorly to ASA over 12 month follow up with repeat measures; 2) AA-
induced platelet aggregation is not consistent with the PFA closure time, even though both assays are widely used for measuring clinical response to 
aspirin and 2) ASA intake has a minimal impact on ADP induced platelet aggregation and PFA measurements in PAD patients
